Symbiosis Pharmaceutical Services
Symbiosis Pharmaceutical Services (Symbiosis) is a Contract Manufacturing Organisation (CMO) based in Stirling and specialises in the sterile manufacture of injectable biopharmaceutical medicines. Founded in 2011 by CEO Colin MacKay, Symbiosis works with emerging biotech and pharmaceutical companies to manufacture and distribute their life-saving therapies worldwide. Supporting Biotechnology Innovation Operating from an MHRA-licensed, FDA-inspected facility, Symbiosis specialises in the manufacture of complex biologics and small-molecule formulations. Its ability to handle highly potent compounds with regulatory compliance ensures clients receive safe products for clinical and commercial supply. Symbiosis plays a pivotal role in advancing the developments of biotechnology by providing specialised manufacturing of cutting-edge therapies. Its expertise in aseptic processing supports biotech and pharmaceutical firms to develop novel treatments, such as antibody-drug conjugates and gene therapies. By offering integrated analytical testing and GMP storage, Symbiosis accelerates the journey from drug substance to clinical trials, empowering biotech innovators to bring transformative medicines to patients faster, fulfilling a critical niche in the marketplace.
International Trade Excellence Receiving the award in the international trade category is a welcome recognition of the sustained and significant international growth trajectory of Symbiosis, particularly in the US and EU territories. In creating a global business development team Symbiosis has been able to build a strong international client base, expanding its biopharmaceutical manufacturing services across North America, Europe and the APAC region, solidifying the company’s reputation as a trusted partner in delivering life-changing medicines to patients worldwide. Exciting Growth and Innovation In 2024, Symbiosis invested £26m in a new 20,000sq ft facility in Stirling, introducing automated manufacturing, increasing batch capacity, creating 50 new jobs and increasing headcount to 180. Symbiosis’ client-focused approach and operational agility ensure it remains at the forefront of biopharmaceutical innovation, delivering critical medicines with precision and speed. Colin MacKay says, “We’re delighted that our continued commitment to manufacturing excellence and client service has been recognised with the prestigious Kings Award for Enterprise – International Trade 2025.”
SYMBIOSIS PHARMACEUTICAL SERVICES Scion House, Stirling Innovation Park, Stirling, FK9 4NF Tel: 01786 220000 • symbiosis-pharma.com
UTM Ltd
UTM Limited was founded in 2000 and is based in Mildenhall, Suffolk, where all of its ammunition and conversion kits are manufactured. It is the world’s largest manufacturer of training ammunition, specialising in non-lethal rounds for military, law enforcement and security training. These rounds allow the most realistic simulation of real life combat scenarios, without the risks associated with live ammunition. UTM also manufactures blank ammunition, which has many advantages over traditional crimped blanks, such as increased safety and reduced fouling of weapons, as well as greater realism by not requiring a BFA. Essentially, UTM’s products allow for soldiers to be trained quicker, more comprehensively and more safely, resulting in better trained troops with greater lethality. UTM produces conversion kits for over 300 different weapon systems, from pistols, rifles and sub machine guns to belt-fed machine guns. Ammunition calibres include 9mm, 556mm (link and loose 7.62 x 39mm; 7.62 x 51mm), with 6.8mm and 6.5mm in development. With most serious militaries choosing UTM, including most of the UK’s Partner Forces, the company has a strong presence in Europe, with
The British Army training a Partner Force using UTM products and a converted machine gun with UTM non-lethal training ammunition
its other main markets the USA, Middle East and Australia. UTM exports to users in over 60 countries and is proud to win the King’s Award for Enterprise in International Trade. The export strategy is based on the establishment of partnerships, including distributors, resellers to sell directly to end users, and strategic alliances offering complementary services. Overseas sales have grown by 108% over three years and the proportion of sales
exported has increased to 98% of total sales. The company wins the King’s Award for International Trade for Outstanding Short-Term Growth in overseas sales over the last three years. UTM LTD Hampstead Avenue, Mildenhall, Suffolk, IP28 7AS Tel +44 (0)1638 711003 paul.graham@utmworldwide.com www.utmworldwide.com
www. kingsawardsmagazine .com
76
Made with FlippingBook. PDF to flipbook with ease